Physician profile
Michelle Gamio
NPI 1164820643
$2,730.23
in general payments reported to CMS, 2019-2025
29 companies · $606 in 2025
The $606 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $769 · 2022: $478 · 2023: $429 · 2024: $449 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $699.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $259.26 | 2021-2023 | Injectafer |
| Abbott Laboratories | $231.55 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $212.35 | 2022-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.32 | 2021-2025 | Xifaxan |
| Pfizer INC. | $149.66 | 2022-2025 | |
| Amgen INC. | $131.98 | 2021-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $95.16 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $94.54 | 2021 | |
| Astellas Pharma US INC | $92.77 | 2021-2024 | Veozah |
| Glaxosmithkline, LLC. | $78.11 | 2021-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $66.58 | 2021-2025 | |
| Nevro Corp. | $66.41 | 2021-2023 | Senza |
| Esperion Therapeutics, INC. | $49.94 | 2021-2025 | Nexletol |
| Inspire Medical Systems, INC. | $45.33 | 2025 | Inspire |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $39.07 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $37.79 | 2024-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Edwards Lifesciences Corporation | $28.08 | 2025 | Sapien 3 Ultra Resilia |
| Phathom Pharmaceuticals, INC. | $26.13 | 2025 | Voquezna |
| Boston Scientific Corporation | $22.99 | 2023 | Watchman Flx |
| Amarin Pharma, INC. | $19.74 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.35 | 2021 | |
| Genentech USA, INC. | $15.08 | 2021 | |
| Abbvie INC. | $14.28 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.51 | 2021 | |
| Medtronic, INC. | $12.94 | 2022 | |
| Althera Pharmaceuticals LLC | $12.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.54 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Gamio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.